UNC Eshelman School of Pharmacy Highlights
Transcript of UNC Eshelman School of Pharmacy Highlights
-
8/6/2019 UNC Eshelman School of Pharmacy Highlights
1/17
-
8/6/2019 UNC Eshelman School of Pharmacy Highlights
2/17
Fast Facts
No 2 Ranked PharmD program (most recent rankingin US News & World Report)
Ranked #2 in NIH Funding, 2010 105 Faculty , 600 PharmD students, 110 Graduate
students
Over 200,000 sq ft of research/teaching space (3buildings) equipped with state-of-the art VTC and
distance education technology
-
8/6/2019 UNC Eshelman School of Pharmacy Highlights
3/17
PharmD PhD MS
Medicinal
Chemistry
&
Natural
Products
Molecular
Pharmaceutics
Pharmacotherapy
& Exp.
Therapeutics
Pharmaceutical
Outcomes
& Policy
Health System
Pharmacy
Academic Programs
-
8/6/2019 UNC Eshelman School of Pharmacy Highlights
4/17
Center for Integrative
Chemical Biology and
Drug Discovery
Center for Nanotechnology
in Drug Delivery
Institute for
Pharmacogenomics and
Individualized Therapy
Disease Targets
Leads
Pharmaceutical
Scientists
Novel Therapies
Novel Technologies
Formulation and
Drug DeliveryDisposition, Safety &
Efficacy in Clinic
Medicinal Chemistry
and Natural ProductsSynthetic Chemistry
Chemical Biology
Bio- and Chem-informatics
Structural Biology
Target Discovery & Validation
Molecular
PharmaceuticsDrug DeliveryFormulation
Gene Delivery
Nanotechnology
Material Science
Bioengineering
Pharmacotherapy
and ExperimentalTherapeuticsDrug Metabolism & transport
Pharmacogenomics
PK/PD Modeling & Simulation
Clinical Trial Design
Clinical Pharmacology
-
8/6/2019 UNC Eshelman School of Pharmacy Highlights
5/17
Discovery to Practice
Formulation and
Drug delivery
Molecular
Pharmaceutics
Disease targets,
Leads
Medicinal
Chemistry
&Natural
Products
Disposition,
Safety and
Efficacy in clinic
Pharmacotherapy
&
Experimental
Therapeutics
Effectiveness of
delivery,
Compliance
Pharmaceutical
Outcomes
&
Policy
Pharmacy
Practice &
Experiential
Education
Evaluation,
Development,
Education
Discovery Optimization Assessment Outcomes Practice
-
8/6/2019 UNC Eshelman School of Pharmacy Highlights
6/17
Center for Integrative Chemical Biology
& Drug Discovery (CICBDD)
Vision: The Center will be an innovative and sustainable scientific force in the creation of new small molecule therapeutics to improve
public health and to transform the drug discovery paradigm.
Center Capabilities
small
molecule
probes
drug
leads
target
validation
Target
Proposals
from
UNC Faculty
responsive
collaborations
Center
Initiated
Projects in
Chemical
Biology
prospective
science
CICBDD staff
& joint facultyAssay Development
Protein expression and purification
Cell-based or in vitroMultiple platforms and readouts
Compound ScreeningUp to 100K compounds possible
HTS
Medicinal ChemistrySAR projects11 internal chemists + 4 FTEs in
China and access to more as needed
Compound synthesis
Computational ChemistryDesign of screening sets
Virtual screening
Structure-based design
Director:
Stephen Frye
Features of CICBDD
Access to novel biological targets discovered by UNC facultyacross therapeutics areas
- targets validated with small molecules
Research focus on innovative targets in chromatin biology & epigentics NCI-designated Comprehensive Chemical Biology Center Leadership with industrial track record of discovery of FDA
approved drugs
-
8/6/2019 UNC Eshelman School of Pharmacy Highlights
7/17
The Center for Nanotechnology in Drug Delivery
(CNDD)
Th e f o cu s o f t h e CN DD is t o sa f e ly a n d e f fec t ive l y
t r a n s la t e n e w d r u g a n d im a g i n g d i s co v e r i e s in t o c lin i c a l
t r ia ls u s i n g n a n o t e ch n o lo g y w it h t h e g o a l t o im p r o v e h u m a n
h e a l t h .
Center for Nanotechnology in Drug Delivery (CNDD)
Five Critical
Areas/Disciplines:
1
Chemistry &
Biomaterials
Inst. for AdvancedMaterials
2
Formulation &
Drug Delivery
School ofPharmacy
3
Therapeutic &
Diagnostic Targets
Carolina Center of CancerNanobiotechnology Excellence
4
Nanotoxicology
RTP EPA, NIEHS
5
Phase I/II
Clinical Trials
UNC CTSA
CNDD Academic
Objectives:World leader in research,
training, and intellectual
property creation
CNDD Science
Objectives:First in human, proof of
safety and utility
CNDD Business
Objectives:Sustainable business
Model with ROI for
All stakeholders
CNDD StakeholdersFederal Agencies (NIH, NSF) State of NC
Private sector (VC, Industry) UNC students
UNC Academic/Research Units UNC-Chapel Hill
Director: Russ Mumper
-
8/6/2019 UNC Eshelman School of Pharmacy Highlights
8/17
The Hamner-UNC Institute for Drug Safety Sciences (IDSS)
in vitro in vivo postmarketingsurveillanceclinical
Computational Systems Modeling
Predictive Safety Assessment
A Platform for Integrated Drug Safety Research
Mission: Integrate clinical medicine with cutting-edge systems
biology and in silico modeling platforms to make drugs safer and
advance drug development.
Director: Paul Watkins
-
8/6/2019 UNC Eshelman School of Pharmacy Highlights
9/17
The Vital Partnership of Drug Discovery + Drug Delivery in Clinical Development
New Molecular Entities(problems)
Small moleculesUnstable
Insoluble
Efflux substrates
Poor permeability
Nucleic-acid basedUnstable
Poor permeability
Require intracellular
Accumulation
Peptides/proteinsUnstable
Poor permeability
Facilitate in-vitro screening
Stabilize NMEs
Increase cell accumulation
Range of dosage forms for various
routes of administration in pre-
clinical animal efficacy models
Advantageously affect ADME and
pharmacokinetics
Minimize toxicity, Safe (GRAS
materials)
Cost-effective
Scalable under GMP
CMC sections of IND
The Essence of Skills in the
Center for Nanotechnology in Drug Delivery
Drug Discovery Drug Delivery
+IIncreasedProbability
of Clinical
Success
-
8/6/2019 UNC Eshelman School of Pharmacy Highlights
10/17
Associate Directors:Oncology researchFederico Innocenti
Pre-clinical PGxTimothy Wiltshire
Policy and EthicsLynn Dressler
PGx Applied Technology
Karen Weck
Clinical PGxJames Evans
PGx Evidence-basedPracticesDan Jonas
IPIT is a collaboration of investigators, scientists,and clinicians across allied health schools within UNC with the
unifying goalof expediting the path from basic research
discoveries to clinical practice.
Preclinical Pharmacogenomics
Policy & Ethics
Applied Technology
Clinical PharmacogenomicsMedical Decision Making/Outcomes
Phenotype-driven therapy
Evidence-based medicine
Pharmaco-economics
School of Pharmacy
School of Medicine
School of Public Health
School of Nursing
Lineberger
Comprehensive
Cancer Center
Carolina Center
for Genome Sciences
IPIT
Research Areas
Director:
Howard McLeod
-
8/6/2019 UNC Eshelman School of Pharmacy Highlights
11/17
Translational Biomedical Research at UNC
Depts. Chemistry, Physics, Mathematics,
& Computer Science
Institute for Advanced Materials,Nanoscience and Technology (IAM)
Biomedical Research Imaging Center (BRIC)
Carolina Center of CancerNanotechnology Excellence (CCCNE)
North Carolina Center forNanoscale Materials (NCCNM)
Biomanufacturing Research Instituteand Technology Enterprise (BRITE)
Partial List of Key Partners:
Bryson Center for Human Genetics
North Carolina Translational and ClinicalSciences (TraCS) Institute (via NIH CTSA)
School of Medicine
Chemistry & Biology- High-throughout synthesis & screening- Bioassay development- Cheminformatics
Nanotechnology & Engineering- Materials discovery; Nanoengineering- Pharmaceutics; formulations- Biological stability; Nanotoxicology
Validated targetsConfirmed leads
Stable, lead formulations
In-VivoScreening
- Biological transport; delivery- Pharmacokinetics; ADME
Efficacious pre-clinical lead formulations
Genomics & Biology- Gene expression- Pharmacogenomics
Link molecular genetics to efficacy
CICBDD
IPIT
CenterforExp
loratoryCheminf
ormaticsResearch
Research TrianglePark
IndustryIndustry
Lineberger ComprehensiveCancer Center (LCCC)
UNC Institute for Nanomedicine
UNC Neuroscience Center
Carolina Cardiovascular Biology Center
-
8/6/2019 UNC Eshelman School of Pharmacy Highlights
12/17
Area Universities Pharmacy Spinoffs
Oriel Therapeutics
Research Triangle Park (RTP)
Pharma/Biotech companies
Relationships
Qualiber
UNC
Capture Pharmaceuticals
NeuroGate
-
8/6/2019 UNC Eshelman School of Pharmacy Highlights
13/17
Chemical Biology and Medicinal Chemistry
David
Lawrence, Ph.D.
Michael
Jarstfer, Ph.D.
Andrew
Lee, Ph.D.
Stephen
Frye, Ph.D.
Chemoinformatics,Bioinformatics, & Computation
Alexander
Tropsha, Ph.D.
Jian
Liu, Ph.D.
Glycobiology
BryanRoth, MD, Ph.D.
NIMH-PsychoactiveDrug Screening Program
Rihe
Liu, Ph.D.
Functional
Proteomics
Harold
Kohn, Ph.D.
Qisheng
Zhang, Ph.D.
K.H.
Lee, Ph.D.
Natural Products
-
8/6/2019 UNC Eshelman School of Pharmacy Highlights
14/17
Formulation & Drug Delivery
SamLai, Ph.D.
RussMumper, Ph.D.
MooCho, Ph.D.
RudyJuliano, Ph.D.
Michael
Jay, Ph.D.
LeafHuang, Ph.D.
Protein Dynamics NMR
Andrew
Lee, Ph.D.
Radiopharmaceutics
& Imaging
MichaelJay, Ph.D. RichardKowalski, Ph.D.
Pediatric Pharmacotherapy
Angela Kashuba,
PharmDDhiren
Thakker, Ph.D.
Michael
Cohen-Wolkoweitz
-
8/6/2019 UNC Eshelman School of Pharmacy Highlights
15/17
Metabolism/Transport/PK/PD/Pharmacometrics
Kim Brouwer
PharmD, Ph.D.
Dhiren
Thakker, Ph.D.
Mary
Paine Ph.D.
Philip
Smith, Ph.D.
Julie Dumond,
PharmD
Adam
Persky, Ph.D.
Cardiovascular Pharmacology
Craig Lee,
PharmD, Ph.D.
Herbert,
Patterson PharmD
Jo Ellen Rodgers,
PharmD
Mechanisms of Hepatotoxicity
Kim Brouwer
PharmD, Ph.D.Roy Hawke
PharmD, Ph.D.Paul Watkins,
M.D.
-
8/6/2019 UNC Eshelman School of Pharmacy Highlights
16/17
Infectious Diseases
Angela Kashuba,
PharmD
William Zamboni,
PhD, PharmD
Amanda
Corbett, PharmD
Julie Dumond,PharmD
Russ Mumper,PhD
Pharmacogenomics/Cancer Parmacotherapy
Howard McLeod,
PharmD
Tim
Wiltshire, Ph.D.
Lynn
Dressler, DrPH Federico Innocenti,MD, Ph.D.
William Zamboni,
PhD, PharmD
Christine
Walko, PharmD
SamLai, Ph.D.
-
8/6/2019 UNC Eshelman School of Pharmacy Highlights
17/17
Outcomes Research
Betsy
Sleath, Ph.D.
Mary
Roth McClurg, Ph.D.Susan Blalock,
MPH, Ph.D.Joel
Farley, Ph.D.
LynnDressler, DrPH
JayaRao, MD
Transplant Pharmacotherapy
RobertDupuis, PharmD